Source: Annual Congress 2005 - Treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. H. Jung, H. K. Kim, C. H. Oak, T. W. Jang, C. H. Jeon (Busan, Daegu, Republic Of Korea). Relation between ERCC1 expression in sputum and survival after cisplatin-based chemotherapy in non-small cell lung cancer. Eur Respir J 2005; 26: Suppl. 49, 595

Member's Comments

No comment yet.

Related content which might interest you: Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 771s Year: 2006 Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy Source: Eur Respir Rev 2013; 22: 565-576 Year: 2013 Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Comparison of quality of life in patients with non-small cell lung cancer treated by chemotherapy or radiotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004 Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005 Survival of elderly patients with non-small lung cancer tretaed with combined chemotherapy and radiotherapy Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 244–259 Year: 2009 Combined radiotherapy for nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Correlation between parameters of quality of life in patients with non-small cell lung cancer treated by chemotherapy and radiotherapy Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Adjuvant chemotherapy in stage IB nonsmall cell lung cancer Source: Breathe 2009; 5: 361 Year: 2009